Candriam Luxembourg S.C.A. reduced its position in shares of Shire PLC (NASDAQ:SHPG) by 35.7% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 4,055 shares of the biopharmaceutical company’s stock after selling 2,251 shares during the quarter. Candriam Luxembourg S.C.A.’s holdings in Shire were worth $629,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Harding Loevner LP boosted its holdings in shares of Shire by 18,894.4% during the 3rd quarter. Harding Loevner LP now owns 127,537,052 shares of the biopharmaceutical company’s stock worth $20,354,000 after buying an additional 126,865,607 shares during the period. Boston Partners boosted its holdings in shares of Shire by 60.9% during the 4th quarter. Boston Partners now owns 2,342,391 shares of the biopharmaceutical company’s stock worth $363,351,000 after buying an additional 886,572 shares during the period. Janus Henderson Group PLC boosted its holdings in shares of Shire by 35.3% during the 3rd quarter. Janus Henderson Group PLC now owns 1,740,973 shares of the biopharmaceutical company’s stock worth $266,613,000 after buying an additional 454,092 shares during the period. Ameriprise Financial Inc. boosted its holdings in shares of Shire by 6.4% during the 3rd quarter. Ameriprise Financial Inc. now owns 1,606,342 shares of the biopharmaceutical company’s stock worth $245,997,000 after buying an additional 96,115 shares during the period. Finally, Third Point LLC bought a new stake in shares of Shire during the 3rd quarter worth $183,768,000. 20.92% of the stock is owned by institutional investors and hedge funds.
SHPG has been the subject of several recent analyst reports. Piper Jaffray Companies reaffirmed a “hold” rating and set a $160.00 price objective on shares of Shire in a report on Friday, October 27th. Zacks Investment Research raised shares of Shire from a “sell” rating to a “hold” rating in a report on Friday, October 27th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $222.00 price objective on shares of Shire in a report on Friday, October 27th. Cowen set a $225.00 price objective on shares of Shire and gave the stock a “buy” rating in a report on Sunday, October 29th. Finally, FBR & Co reaffirmed a “buy” rating and set a $201.00 price objective on shares of Shire in a report on Monday, October 30th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and twelve have assigned a buy rating to the stock. Shire has a consensus rating of “Buy” and an average target price of $204.00.
Shire (NASDAQ:SHPG) last announced its earnings results on Wednesday, February 14th. The biopharmaceutical company reported $3.98 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.86 by $0.12. The business had revenue of $4.14 billion during the quarter. Shire had a net margin of 28.17% and a return on equity of 14.19%. The company’s revenue for the quarter was up 8.9% compared to the same quarter last year. During the same quarter last year, the business earned $3.37 EPS. analysts expect that Shire PLC will post 15.24 earnings per share for the current fiscal year.
The company also recently announced a semiannual dividend, which will be paid on Tuesday, April 24th. Investors of record on Friday, March 9th will be given a dividend of $0.8937 per share. The ex-dividend date is Thursday, March 8th. This represents a dividend yield of 1.33%. This is a boost from Shire’s previous semiannual dividend of $0.15. Shire’s dividend payout ratio (DPR) is 15.16%.
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.